Literature DB >> 2232809

Carcinoma of the pancreas: a retrospective review.

G J Harris1, H V Gaskill, A B Cruz.   

Abstract

Eighty-five patients with adenocarcinoma of the pancreas were reviewed in order to evaluate the efficacy of our methods of diagnosis and treatment. The most useful diagnostic test was percutaneous transhepatic cholangiography (PTC) with a diagnostic rate of 96%. Pancreaticoduodenectomy (Whipple procedure) and total pancreatic resection were performed in 13 and 2 patients, respectively. The remaining 50 patients underwent various palliative drainage procedures. Twenty patients did not undergo operation for various reasons. The primary tumor was found in the head of the pancreas in 50 patients (59%), the body in 6 patients (7%), and in the tail in 8 patients (9%). Postoperative complications, including sepsis, bleeding, intra-abdominal abscesses, and anastomotic leaks, occurred in 37% of the patients. There were one operative and 9 postoperative deaths. The average survival for those patients undergoing surgical intervention was 6 months. There were no 5-year survivors.

Entities:  

Mesh:

Year:  1990        PMID: 2232809     DOI: 10.1002/jso.2930450311

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry.

Authors:  M Carpelan-Holmström; S Nordling; E Pukkala; R Sankila; J Lüttges; G Klöppel; C Haglund
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

2.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors.

Authors:  K C Conlon; D S Klimstra; M F Brennan
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

3.  Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.

Authors:  Juan Enrique Domínguez-Muñoz; Laura Nieto-Garcia; Javier López-Díaz; Jose Lariño-Noia; Ihab Abdulkader; Julio Iglesias-Garcia
Journal:  BMC Cancer       Date:  2018-05-05       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.